Evidence map›Paper›PMID 39347610›Full record

ArticleCancer2024

The American Cancer Society National Lung Cancer Roundtable strategic plan: Promoting guideline-concordant lung cancer staging.

Farhood Farjah, Julie A Barta, Douglas E Wood, M Patricia Rivera, Raymond U Osarogiagbon, Robert A Smith, Timothy W Mullett, Lauren S Rosenthal, Louise M Henderson, Frank C Detterbeck and 1 more

Abstract read
In one paragraph

Article in Cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Farhood FarjahDepartment of Surgery, University of Washington, Seattle, Washington, USA.ORCID https://orcid.org/0000-0002-5205-3804
Julie A BartaDivision of Pulmonary and Critical Care Medicine, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Douglas E WoodDepartment of Surgery, University of Washington, Seattle, Washington, USA.
M Patricia RiveraDepartment of Medicine, Division of Pulmonary and Critical Care Medicine, Wilmot Cancer Institute, The University of Rochester Medical Center, Rochester, New York, USA.ORCID https://orcid.org/0000-0003-3827-5010
Raymond U OsarogiagbonMultidisciplinary Thoracic Oncology Program, Baptist Cancer Center, Memphis, Tennessee, USA.
Robert A SmithEarly Cancer Detection Science, American Cancer Society, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0003-3344-2238
Timothy W MullettDepartment of Surgery, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
Lauren S RosenthalEarly Cancer Detection Science, American Cancer Society, Atlanta, Georgia, USA.
Louise M HendersonDepartment of Radiology, University of North Carolina, Chapel Hill, North Carolina, USA.ORCID https://orcid.org/0000-0001-8356-9267
Frank C DetterbeckDivision of Thoracic Surgery, Yale University, New Haven, Connecticut, USA.
Gerard A SilvestriDivision of Pulmonary and Critical Care Medicine, Medical University of South Carolina, Charleston, South Carolina, USA.

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
American Cancer Society National Lung Cancer RoundtableNCATS NIH HHS UL1 TR001863
6 · The paper itself

Abstract

Accurate staging improves lung cancer survival by increasing the chances of delivering stage-appropriate therapy. However, there is underutilization of, and variability in, the use of guideline-recommended diagnostic tests used to stage lung cancer. Consequently, the American Cancer Society National Lung Cancer Roundtable (ACS NLCRT) convened the Triage for Appropriate Treatment Task Group-a multidisciplinary expert and stakeholder panel-to identify knowledge and/or resource gaps contributing to guideline-discordant staging and make recommendations to overcome these gaps. The task group determined the following: Gap 1: facilitators of and barriers to guideline-concordant staging are incompletely understood; Recommendation 1: identify facilitators of and barriers to guideline-concordant lung cancer staging; Gap 2: the level of evidence supporting staging algorithms is low-to-moderate; Recommendation 2: prioritize comparative-effectiveness studies evaluating lung cancer staging; Gap 3: guideline recommendations vary across professional societies; Recommendation 3: harmonize guideline recommendations across professional societies; Gap 4: existing databases do not contain sufficient information to measure guideline-concordant staging; Recommendation 4: augment existing databases with the information required to measure guideline-concordant staging; Gap 5: health systems do not have a performance feedback mechanism for lung cancer staging; Recommendation 5: develop and implement a performance feedback mechanism for lung cancer staging; Gap 6: patients rarely self-advocate for guideline-concordant staging; Recommendation 6: increase opportunities for patient self-advocacy for guideline-concordant staging; and Gap 7: current health policies do not motivate guideline-concordant lung cancer staging; Recommendation 7: organize a representative working group under the ACS NLCRT that promotes policies that motivate guideline-concordant lung cancer staging. PLAIN LANGUAGE SUMMARY: Staging-determining the degree of cancer spread-is important because it helps clinicians choose the best cancer treatment. Receiving the best cancer treatment leads to the best possible patient outcomes. Practice guidelines are intended to help clinicians stage patients with lung cancer. However, lung cancer staging in the United States often varies from practice guideline recommendations. This report identifies seven opportunities to improve lung cancer staging.

Indexed as

American Cancer SocietyLung NeoplasmsNeoplasm StagingGuideline AdherenceHumansPractice Guidelines as TopicUnited Stateslung neoplasmsmediastinal stagingneoplasm stagingnon–small cell lung cancerquality improvement

Identifiers

PMID39347610
PMCPMC11585343

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.